Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Therapeutic applications of the ΦC31 integrase system.

Chavez CL, Calos MP.

Curr Gene Ther. 2011 Oct;11(5):375-81. Review.

PMID:
21888619
2.

The phiC31 integrase system for gene therapy.

Calos MP.

Curr Gene Ther. 2006 Dec;6(6):633-45. Review.

PMID:
17168696
3.
4.

The therapeutic potential of ΦC31 integrase as a gene therapy system.

Karow M, Calos MP.

Expert Opin Biol Ther. 2011 Oct;11(10):1287-96. doi: 10.1517/14712598.2011.601293. Epub 2011 Jul 8. Review.

PMID:
21736536
5.

[Progress of φC31 integrase system in site-specific integration].

Ma QW.

Yi Chuan. 2011 Jun;33(6):567-75. Review. Chinese.

PMID:
21684861
6.

Integrase-defective lentiviral vectors--a stage for nonviral integration machineries.

Staunstrup NH, Mikkelsen JG.

Curr Gene Ther. 2011 Oct;11(5):350-62. Review.

PMID:
21745178
7.

Integrase-defective lentiviral vectors: progress and applications.

Banasik MB, McCray PB Jr.

Gene Ther. 2010 Feb;17(2):150-7. doi: 10.1038/gt.2009.135. Epub 2009 Oct 22. Review.

PMID:
19847206
8.

Transposon-mediated gene transfer into adult and induced pluripotent stem cells.

Belay E, Dastidar S, VandenDriessche T, Chuah MK.

Curr Gene Ther. 2011 Oct;11(5):406-13. Review.

PMID:
21864290
9.

Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients.

Romano G, Marino IR, Pentimalli F, Adamo V, Giordano A.

Drug News Perspect. 2009 May;22(4):185-96. doi: 10.1358/dnp.2009.22.4.1367704. Review.

PMID:
19536363
10.

Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies.

Ohlfest JR, Freese AB, Largaespada DA.

Curr Gene Ther. 2005 Dec;5(6):629-41. Review.

PMID:
16457652
11.

Genome-wide manipulations of Drosophila melanogaster with transposons, Flp recombinase, and ΦC31 integrase.

Venken KJ, Bellen HJ.

Methods Mol Biol. 2012;859:203-28. doi: 10.1007/978-1-61779-603-6_12. Review.

PMID:
22367874
12.

Non-integrating lentiviral vectors.

Sarkis C, Philippe S, Mallet J, Serguera C.

Curr Gene Ther. 2008 Dec;8(6):430-7. Review.

PMID:
19075626
13.

Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells.

VandenDriessche T, Ivics Z, Izsvák Z, Chuah MK.

Blood. 2009 Aug 20;114(8):1461-8. doi: 10.1182/blood-2009-04-210427. Epub 2009 May 26. Review.

14.

Development of adenovirus hybrid vectors for Sleeping Beauty transposition in large mammals.

Hausl M, Zhang W, Voigtländer R, Müther N, Rauschhuber C, Ehrhardt A.

Curr Gene Ther. 2011 Oct;11(5):363-74. Review.

PMID:
21888620
15.

Awakening gene therapy with Sleeping Beauty transposons.

Essner JJ, McIvor RS, Hackett PB.

Curr Opin Pharmacol. 2005 Oct;5(5):513-9. Review.

PMID:
16084771
16.

Viral hybrid-vectors for delivery of autonomous replicons.

Zhang W, Hagedorn C, Schulz E, Lipps HJ, Ehrhardt A.

Curr Gene Ther. 2014 Feb;14(1):10-23. Review.

PMID:
24365145
17.

Gene, stem cell, and future therapies for orphan diseases.

Phillips MI.

Clin Pharmacol Ther. 2012 Aug;92(2):182-92. doi: 10.1038/clpt.2012.82. Epub 2012 Jun 27. Review.

PMID:
22739143
18.

Integrase-deficient lentivirus: opportunities and challenges for human gene therapy.

Liu KC, Lin BS, Gao AD, Ma HY, Zhao M, Zhang R, Yan HH, Yi XF, Lin SJ, Que JW, Lan XP.

Curr Gene Ther. 2014;14(5):352-64. Review.

PMID:
25174579
19.

New applications for phage integrases.

Fogg PC, Colloms S, Rosser S, Stark M, Smith MC.

J Mol Biol. 2014 Jul 29;426(15):2703-16. doi: 10.1016/j.jmb.2014.05.014. Epub 2014 May 22. Review.

Items per page

Supplemental Content

Write to the Help Desk